BRPI0807154B8 - uso de meta arsenito de sódio para o tratamento de dor - Google Patents

uso de meta arsenito de sódio para o tratamento de dor

Info

Publication number
BRPI0807154B8
BRPI0807154B8 BRPI0807154A BRPI0807154A BRPI0807154B8 BR PI0807154 B8 BRPI0807154 B8 BR PI0807154B8 BR PI0807154 A BRPI0807154 A BR PI0807154A BR PI0807154 A BRPI0807154 A BR PI0807154A BR PI0807154 B8 BRPI0807154 B8 BR PI0807154B8
Authority
BR
Brazil
Prior art keywords
treatment
arsenic
pain treatment
sodium arsenite
pain
Prior art date
Application number
BRPI0807154A
Other languages
English (en)
Inventor
Hwang Michael
Yang Yong-Jin
Original Assignee
Panaphix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panaphix Inc filed Critical Panaphix Inc
Publication of BRPI0807154A2 publication Critical patent/BRPI0807154A2/pt
Publication of BRPI0807154B1 publication Critical patent/BRPI0807154B1/pt
Publication of BRPI0807154B8 publication Critical patent/BRPI0807154B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

uso de compostos de arsênio para o tratamento de dor e inflamação a presente invenção relaciona-se ao uso de compostos de arsênio como meta arsenito de sódio (naaso2), trióxido de arsênio (as2o3), e hexóxido de arsênio (as4o6) ou combinações destes, para o tratamento de condições dolorosas, hiperalgésicas e/ou inflamatórias. a presente invenção também se relaciona às composições que contêm os compostos de arsênio acima para uso no tratamento de dor, inflamação e doenças e distúrbios imunológicos e autoimunes.
BRPI0807154A 2007-02-02 2008-02-01 uso de meta arsenito de sódio para o tratamento de dor BRPI0807154B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89900707P 2007-02-02 2007-02-02
US60/899,007 2007-02-02
US12/068,006 US8945505B2 (en) 2007-02-02 2008-01-31 Use of arsenic compounds for treatment of pain and inflammation
US12/068.006 2008-01-31
PCT/US2008/052751 WO2008097824A2 (en) 2007-02-02 2008-02-01 Use of arsenic compounds for treatment of pain and inflammation

Publications (3)

Publication Number Publication Date
BRPI0807154A2 BRPI0807154A2 (pt) 2014-04-22
BRPI0807154B1 BRPI0807154B1 (pt) 2021-01-12
BRPI0807154B8 true BRPI0807154B8 (pt) 2021-05-25

Family

ID=39322911

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807154A BRPI0807154B8 (pt) 2007-02-02 2008-02-01 uso de meta arsenito de sódio para o tratamento de dor

Country Status (19)

Country Link
US (2) US8945505B2 (pt)
EP (1) EP2114419B8 (pt)
JP (3) JP5411709B2 (pt)
KR (1) KR101479519B1 (pt)
CN (2) CN103550253A (pt)
AR (1) AR065138A1 (pt)
AU (1) AU2008214084C9 (pt)
BR (1) BRPI0807154B8 (pt)
CA (3) CA2845299C (pt)
DK (1) DK2114419T3 (pt)
ES (1) ES2460868T3 (pt)
HK (1) HK1138512A1 (pt)
IL (3) IL200173A (pt)
MX (1) MX2009008174A (pt)
NZ (1) NZ578621A (pt)
PL (1) PL2114419T3 (pt)
RU (3) RU2630574C2 (pt)
TW (1) TWI404538B (pt)
WO (1) WO2008097824A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090061022A1 (en) * 2004-10-08 2009-03-05 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8045505B2 (en) * 2007-01-18 2011-10-25 Science Applications International Corporation Mechanism for automatic network formation and medium access coordination
CN101959528A (zh) 2008-03-04 2011-01-26 辉瑞有限公司 治疗慢性疼痛的方法
JP6049455B2 (ja) * 2009-05-18 2016-12-21 ザ ユニバーシティ オブ ホンコンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｈｏｎｇ Ｋｏｎｇ 炎症性関節炎を治療するための組成物および方法
EP3165236B1 (en) 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
KR20120061908A (ko) * 2009-09-10 2012-06-13 코미녹스 인코포레이티드 암 줄기세포-표적 및 약물 내성 암 치료
FR3004949B1 (fr) * 2013-04-26 2016-02-05 Centre Nat Rech Scient Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale
PE20220337A1 (es) 2014-03-21 2022-03-14 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR102015858B1 (ko) * 2015-10-23 2019-08-30 손영태 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
KR101844049B1 (ko) * 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
CN106890353A (zh) * 2017-03-31 2017-06-27 应剑波 一种具有抗菌滋养功能的医用辅料
US10716807B2 (en) * 2017-05-09 2020-07-21 Medsenic Method of treating relapsing-remitting multiple sclerosis using arsenic trioxide
JP7419333B2 (ja) * 2018-03-22 2024-01-22 コミファーム インターナショナル オーストラリア ピーティーワイ リミテッド メタ亜ヒ酸塩を含む医薬組成物および製造方法
RU2687599C1 (ru) * 2018-11-22 2019-05-15 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения постмастэктомического синдрома
CN109674817B (zh) * 2019-01-31 2021-06-29 哈尔滨医科大学 三氧化二砷在制备治疗晚期动脉粥样硬化药物中的用途
CA3170519A1 (en) * 2020-02-16 2021-08-19 Komipharm International Australia Pty Ltd Method of treatment using meta-arsenite
RU2755329C2 (ru) * 2020-03-13 2021-09-15 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ /ФГБУ "РНЦРХТ им. академика А.М. Гранова" Минздрава России Способ лечения нерезектабельной гилюсной холангиокарциномы
EP3988093A1 (en) * 2020-10-22 2022-04-27 Medsenic Use of an arsenic compound for treating a cytokine storm
EP4125863A1 (en) * 2020-04-03 2023-02-08 Medsenic Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals
KR102240693B1 (ko) * 2020-05-18 2021-04-15 주식회사 케마스 육산화사비소를 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학조성물
KR20220020637A (ko) * 2020-08-12 2022-02-21 이상봉 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물
KR20220020633A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 주사제 조성물
US20220228142A1 (en) 2020-12-17 2022-07-21 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536273A (en) * 1895-03-26 Tavus rein
US1498639A (en) * 1919-12-02 1924-06-24 David S Pratt Arsenical composition and method of making same
US3622664A (en) * 1968-11-21 1971-11-23 John A Brown Treatment of infectious keratitis in animals with sodium arsenite
SU955909A1 (ru) * 1980-06-25 1982-09-07 Центральный Ордена Ленина Институт Усовершенствования Врачей Способ профилактики осложнений при пересадке тканей
US4677974A (en) * 1985-09-30 1987-07-07 David Leonardi Method and apparatus for immobilizing an eyelid
CA2051012C (en) 1990-09-14 2002-04-02 David R. Borcherding Carbocyclic adenosine analogs useful as immunosupressants
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
CA2183547C (en) 1994-02-18 2002-05-14 Tamara Vasilievna Vorobieva Compositions for treating defective cell functions
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
IT1272994B (it) * 1994-05-25 1997-07-01 Giampiero Valletta Uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario.-
IT1295067B1 (it) * 1997-09-25 1999-04-27 Walter Tarello Uso di arsenico per preparare un medicamento per il trattamento della sindrome premestruale
PT1621077E (pt) 1997-10-15 2008-11-04 Polarx Biopharmaceuticals Inc Composições farmacêuticas compreendendo trióxido de arsénico para o tratamento de um tumor do sistema nervoso central
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
US6919343B2 (en) * 2002-02-08 2005-07-19 Merck & Co., Inc. N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
RU2310460C2 (ru) * 2002-04-10 2007-11-20 Корея Микробиолоджикал Лабораторис, Лтд. Фармацевтическая композиция для лечения злокачественной опухоли, содержащая арсенит натрия
ES2425418T3 (es) 2002-04-10 2013-10-15 Komipharm International Co., Ltd. Composición farmacéutica que comprende arsenito para el tratamiento de neoplasias
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
JP2005206591A (ja) * 2003-12-25 2005-08-04 Mitsubishi Pharma Corp 神経因性疼痛の予防及び／又は治療のための医薬
US20080096872A1 (en) * 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
JP2006206461A (ja) 2005-01-26 2006-08-10 Teizo Chinen アレルギー疾患の予防・治療用組成物
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases

Also Published As

Publication number Publication date
TWI404538B (zh) 2013-08-11
AU2008214084C9 (en) 2014-04-03
JP2015007138A (ja) 2015-01-15
EP2114419A2 (en) 2009-11-11
US20080193560A1 (en) 2008-08-14
IL229255A0 (en) 2013-12-31
AR065138A1 (es) 2009-05-20
PL2114419T3 (pl) 2014-10-31
JP5825611B2 (ja) 2015-12-02
IL217891A (en) 2014-05-28
AU2008214084C1 (en) 2014-03-06
AU2008214084A1 (en) 2008-08-14
IL229255A (en) 2015-02-26
JP5853347B2 (ja) 2016-02-09
RU2009132951A (ru) 2011-03-10
US20130309319A1 (en) 2013-11-21
IL200173A (en) 2013-12-31
RU2012134218A (ru) 2014-02-20
WO2008097824A3 (en) 2009-03-26
BRPI0807154B1 (pt) 2021-01-12
RU2665362C2 (ru) 2018-08-29
JP5411709B2 (ja) 2014-02-12
IL200173A0 (en) 2010-04-15
EP2114419B8 (en) 2014-06-11
KR20090122348A (ko) 2009-11-27
CA2845299A1 (en) 2008-08-14
US8945505B2 (en) 2015-02-03
CA2845299C (en) 2017-03-07
CA2845292C (en) 2017-09-12
CN103550253A (zh) 2014-02-05
CN101641105A (zh) 2010-02-03
ES2460868T3 (es) 2014-05-14
CA2677388C (en) 2017-07-25
JP2013147511A (ja) 2013-08-01
DK2114419T3 (da) 2014-06-10
JP2010518022A (ja) 2010-05-27
AU2008214084B2 (en) 2013-10-31
EP2114419B1 (en) 2014-04-09
RU2013151904A (ru) 2015-05-27
KR101479519B1 (ko) 2015-01-08
HK1138512A1 (en) 2010-08-27
TW200843734A (en) 2008-11-16
CA2677388A1 (en) 2008-08-14
CA2845292A1 (en) 2008-08-14
IL217891A0 (en) 2012-03-29
US10058570B2 (en) 2018-08-28
WO2008097824A2 (en) 2008-08-14
MX2009008174A (es) 2009-11-26
NZ578621A (en) 2011-06-30
RU2468806C2 (ru) 2012-12-10
RU2630574C2 (ru) 2017-09-11
BRPI0807154A2 (pt) 2014-04-22

Similar Documents

Publication Publication Date Title
BRPI0807154B8 (pt) uso de meta arsenito de sódio para o tratamento de dor
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
BR112015020650A2 (pt) inibidores de histona demetilases
UY33280A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112014018471A2 (pt) anticorpos anti-ige m1' e métodos para o seu uso
BRPI0911031B8 (pt) compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
CL2012002896A1 (es) Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
BR112012019437A2 (pt) 5-alquinil-pirimidinas
BR112012010531A2 (pt) "polipeptídeos de modificação meningocócica fhbp"
BR112014005358A2 (pt) composição para alívio da dor, compreendendo um agonista seletivo de trpv1, e a sua fabricação e utilização
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
BR112015024846A2 (pt) composições para utilização no estímulo do crescimento ósseo
BR112013004562A2 (pt) 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
BR112015004306A2 (pt) fluorometil-substituído pirrol carboxamidas
BR112013004721A2 (pt) "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3"
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF